What are the diagnosis and treatment options for Congestive Heart Failure (CHF)?

Diagnosis and Treatment of Congestive Heart Failure

Diagnosis

Diagnose heart failure through clinical assessment combined with echocardiography to measure left ventricular ejection fraction (LVEF), and use natriuretic peptides (BNP or NT-proBNP) as an exclusion test due to their high negative predictive value. 1

Clinical Assessment

• Identify key symptoms: dyspnea on exertion, fatigue, and signs of fluid retention (peripheral edema, pulmonary congestion) 2, 1
• Classify by LVEF using echocardiography: HFrEF (LVEF ≤40%), HFmrEF (LVEF 40-49%), or HFpEF (LVEF ≥50%) 3, 4
• Assess functional severity using NYHA classification (Class II-IV) to guide treatment intensity 3
• Obtain chest X-ray and ECG in all patients with suspected new-onset heart failure 5
• Identify underlying etiology: coronary artery disease (most common at 68%), hypertension, valvular disease, or cardiomyopathy 6, 5

Diagnostic Testing

• Transthoracic echocardiogram is mandatory to establish diagnosis and determine ejection fraction category 1
• Natriuretic peptides serve as excellent rule-out tests when negative, avoiding unnecessary further workup 1
• Evaluate for precipitating factors: acute coronary syndrome, arrhythmias, medication non-adherence, or infection 3

---

Treatment

All patients with HFrEF must receive triple therapy: ACE inhibitors (or ARBs if intolerant), beta-blockers, and diuretics, with aldosterone antagonists added for NYHA Class III-IV disease. 2, 1, 3

Pharmacological Management for HFrEF

First-Line Therapy (Initiate Simultaneously)

ACE Inhibitors:

• Start ACE inhibitors immediately as first-line therapy to reduce mortality and hospitalizations 2, 1, 3
• Initiation protocol: Review diuretic dose, reduce or withhold diuretics 24 hours before starting, begin with low dose in evening when supine, and titrate to target doses proven in clinical trials 2
• Monitor closely: Check blood pressure, renal function, and electrolytes 1-2 weeks after each dose increase, at 3 months, then every 6 months 2
• If renal function deteriorates substantially, discontinue treatment 2
• Avoid NSAIDs and potassium-sparing diuretics during initiation 2
• If ACE inhibitor intolerant: Use angiotensin receptor blockers (ARBs) as alternative 2, 7

Beta-Blockers:

• Initiate beta-blockers in all stable NYHA Class II-IV patients already on ACE inhibitors and diuretics to improve survival 2, 1, 3
• 89% of patients in major trials were on beta-blockers, though only 26% achieved guideline-defined target doses 6
• Common barriers to target dosing: hypotension (45%), fatigue (32%), dyspnea (14%), dizziness (12%), and bradycardia (6%) 6
• Titrate slowly to maximally tolerated doses despite these side effects when possible 6

Diuretics:

• Essential for all patients with fluid overload (pulmonary congestion or peripheral edema) to rapidly improve dyspnea and exercise tolerance 2, 3, 8
• Always combine with ACE inhibitors 2
• Loop diuretics are first-line (furosemide); thiazides acceptable if GFR >30 ml/min 2
• If inadequate response: Increase dose, combine loop diuretics with thiazides, or administer loop diuretics twice daily 2
• For severe refractory cases: Add metolazone with frequent monitoring of creatinine and electrolytes 2
• If GFR <30 ml/min: Avoid thiazides except when combined synergistically with loop diuretics 2

Additional Therapy for Advanced Disease

Aldosterone Antagonists (Spironolactone):

• Add spironolactone for NYHA Class III-IV patients on ACE inhibitors and diuretics to improve survival and reduce morbidity 2, 1
• Initiation protocol: Start low-dose, check serum potassium and creatinine after 5-7 days, titrate accordingly, and recheck every 5-7 days until stable 2
• Use only if persistent hypokalemia after ACE inhibitor initiation in less severe cases 2

SGLT2 Inhibitors:

• Newer evidence supports SGLT2 inhibitors to improve clinical outcomes and functional status in HFrEF 4

Digoxin:

• Consider for symptomatic improvement, especially with atrial fibrillation, though mortality benefit unproven 2, 7

Ivabradine:

• For stable NYHA Class II-IV patients with LVEF ≤35% and heart rate ≥70 bpm despite maximally tolerated beta-blocker therapy 6
• Reduces hospitalization for worsening heart failure but does not reduce cardiovascular mortality 6
• Dosing: Start 5 mg twice daily, titrate to 7.5 mg or down to 2.5 mg to maintain heart rate 50-60 bpm 6

Special Situations

Atrial Fibrillation:

• Rate control is mandatory in permanent atrial fibrillation 2
• For symptomatic patients: Digoxin is first choice 2
• For asymptomatic patients: Beta-blockers, digoxin, or combination 2
• Consider electrical cardioversion for persistent atrial fibrillation, though success depends on duration and left atrial size 2

Concomitant Angina:

• Optimize beta-blocker dose, consider coronary revascularization, add long-acting nitrates, then second-generation dihydropyridines if unsuccessful 2

Concomitant Hypertension:

• Optimize ACE inhibitors, beta-blockers, and diuretics; add spironolactone or ARBs; then try second-generation dihydropyridines 2

Ventricular Arrhythmias:

• Amiodarone is the preferred agent for severe, symptomatic, sustained ventricular tachycardias 2

---

Non-Pharmacological Management

Patient Education and Self-Care:

• Explain heart failure pathophysiology, symptom recognition, and when to seek help 2, 3
• Teach daily self-weighing and report weight gain >2 kg in 3 days 2, 3
• Emphasize medication adherence to both pharmacological and lifestyle prescriptions 2, 3
• Smoking cessation is mandatory; nicotine replacement acceptable 2, 3

Physical Activity:

• Regular exercise is recommended for stable NYHA Class II-III patients to prevent muscle deconditioning and improve quality of life 2, 3, 4
• Rest is not encouraged in stable conditions 2
• Exercise training programs reduce disability and hospitalization rates 4

Dietary Modifications:

• Control sodium intake in severe heart failure 2, 3
• Avoid excessive fluid intake in severe heart failure 2
• Limit alcohol consumption 3

Multidisciplinary Care:

• Comprehensive disease management programs improve quality of life, reduce readmissions, and decrease costs 2
• Schedule early follow-up within 7 days of hospital discharge 3
• Refer high-risk patients to specialized heart failure programs 3

---

Common Pitfalls to Avoid

• Inadequate diuresis in volume-overloaded patients leads to persistent symptoms 3
• Failure to uptitrate medications to target doses proven in clinical trials reduces survival benefit 3, 6
• Neglecting patient education increases readmission rates 3
• Using NSAIDs or COX-2 inhibitors worsens heart failure and interferes with ACE inhibitor efficacy 2, 8
• Excessive diuresis before ACE inhibitor initiation increases hypotension risk 2
• Starting potassium-sparing diuretics during ACE inhibitor initiation risks dangerous hyperkalemia 2